

Title (en)  
COMBINATION OF CERAMIDE AND OXALIPLATIN FOR INDUCING CELL DEATH AND USES THEREOF IN TREATING CANCER

Title (de)  
KOMBINATION VON CERAMID UND OXALIPLATIN ZUR INDUKTION DES ZELLTODS, UND ANWENDUNGEN DAVON BEI DER BEHANDLUNG VON KREBS

Title (fr)  
COMBINAISON DE CÉRAMIDE ET D'OXALIPLATINE POUR INDUIRE LA MORT CELLULAIRE ET SES UTILISATIONS DANS LE TRAITEMENT DU CANCER

Publication  
**EP 2038248 A4 20130529 (EN)**

Application  
**EP 07795674 A 20070531**

Priority  
• US 2007013077 W 20070531  
• US 81024306 P 20060602

Abstract (en)  
[origin: WO2007143175A2] This invention provides a method for increasing apoptosis in a cancer cell comprising contacting the cancer cell with (a) oxaliplatin and (b) C6-ceramide, sequentially or concomitantly, wherein the oxaliplatin and C6-ceramide are in amounts such that the apoptosis induced by the combination of oxaliplatin and C6-ceramide is greater than the apoptosis induced by contacting the cancer cell with either oxaliplatin alone or C6-ceramide alone. This invention also provides a method of decreasing the size of a tumor, which method comprises contacting the tumor with (a) oxaliplatin and (b) C6-ceramide, sequentially or concomitantly, wherein the oxaliplatin and C6-ceramide are in amounts such that the decrease in tumor size induced by the combination of oxaliplatin and C6-ceramide is greater than the decrease in tumor size induced by contacting the tumor with either oxaliplatin alone or C6-ceramide alone. This invention further provides a pharmaceutical composition and a method for treating a subject afflicted with cancer.

IPC 8 full level  
**C07C 215/00** (2006.01); **A61K 31/282** (2006.01); **A61K 33/243** (2019.01); **A61K 45/06** (2006.01); **C07C 233/00** (2006.01); **C07F 9/00** (2006.01)

CPC (source: EP US)  
**A61K 31/164** (2013.01 - US); **A61K 31/282** (2013.01 - EP US); **A61K 31/555** (2013.01 - US); **A61K 33/243** (2018.12 - EP US); **A61K 45/06** (2013.01 - EP US); **A61P 35/00** (2017.12 - EP)

Citation (search report)  
• [A] YAMADA T ET AL: "Growth inhibition of human pancreatic cancer cells by sphingosylphosphorylcholine and influence of culture conditions", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHAUSER VERLAG, HEIDELBERG, DE, vol. 53, no. 5, May 1997 (1997-05-01), pages 435 - 441, XP002508465, ISSN: 1420-682X, DOI: 10.1007/S000180050052  
• [A] D. E. MODRAK: "Synergistic Interaction between Sphingomyelin and Gemcitabine Potentiates Ceramide-Mediated Apoptosis in Pancreatic Cancer", CANCER RESEARCH, vol. 64, no. 22, 15 November 2004 (2004-11-15), pages 8405 - 8410, XP055060190, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-04-2988  
• See references of WO 2007143175A2

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

Designated extension state (EPC)  
AL BA HR MK RS

DOCDB simple family (publication)  
**WO 2007143175 A2 20071213; WO 2007143175 A3 20080131**; EP 2038248 A2 20090325; EP 2038248 A4 20130529; US 2008033039 A1 20080207; US 2013337040 A1 20131219

DOCDB simple family (application)  
**US 2007013077 W 20070531**; EP 07795674 A 20070531; US 201213730659 A 20121228; US 80941807 A 20070531